The health ministry of the Democratic Republic of Congo approved the use of Merck's new Ebola vaccine to mitigate the spread of an outbreak that has resulted in 52 suspected cases and four deaths, according to a report from Reuters.
The vaccine, dubbed rVSV-ZEBOV, is not yet licensed, but displayed high levels of efficacy in previously reported clinical trials.
Details of the vaccination campaign have not yet been announced.
More articles on infection control:
Scientists reengineer vancomycin to fight superbug
Hot or cool: Water temperature does not impact bacteria removal during hand washing, study shows
Study: 5 risk factors for KPC-producing Enterobacteriaceae